In an interview to CNBC-TV18, Ashok Chawla, Chairperson, CCI, said the order on Sun-Ranbaxy merger is final and that the companies could be given additional 4 months in case the product divestment process exceeds 6 months.
The Sun Pharma - Ranbaxy merger will come into effect after the divestment is complete and the agency is will be monitoring the process, said Ashok Chawla, Chairperson, CCI.
The Competition Commission of India (CCI) on Monday cleared the USD 4 billion deal between Sun Pharma and Ranbaxy but with riders – asking both companies to sell 7 brands, which could have had an appreciable adverse effect on competition in their relevant markets post merger. It has given a 6-month window for the divestment process, post which the deal may get the final nod.
In an interview to CNBC-TV18, Chawla said the order on Sun-Ranbaxy merger is final and that the companies could be given additional 4 months in case the product divestment process exceeds 6 months.
Sun Pharma stock price
On December 09, 2014, at 11:12 hrs Sun Pharmaceutical Industries was quoting at Rs 837.65, up Rs 8.85, or 1.07 percent. The 52-week high of the share was Rs 932.00 and the 52-week low was Rs 552.50.
The latest book value of the company is Rs 35.77 per share. At current value, the price-to-book value of the company was 23.42.
Anda sedang membaca artikel tentang
Sun-Ranbaxy: CCI to monitor drug divestment, says Chawla
Dengan url
https://olahragakecantikan.blogspot.com/2014/12/sun-ranbaxy-cci-to-monitor-drug.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Sun-Ranbaxy: CCI to monitor drug divestment, says Chawla
namun jangan lupa untuk meletakkan link
Sun-Ranbaxy: CCI to monitor drug divestment, says Chawla
sebagai sumbernya
0 komentar:
Posting Komentar